Antiepileptic profile of Parawixin-11, purified from Parawixia bistriata spider venom (Araneae, Araneidae), in Wistar rats.
Parawixia bistriata
Anticonvulsant
Glutamate
Parawixin-11
Spider venom
Journal
Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264
Informations de publication
Date de publication:
23 Jul 2024
23 Jul 2024
Historique:
received:
19
04
2024
accepted:
12
07
2024
medline:
23
7
2024
pubmed:
23
7
2024
entrez:
23
7
2024
Statut:
aheadofprint
Résumé
The pharmacological treatment of epilepsy is often complex due to the lack of efficacy in many patients and profound side effects from current drugs, including sedation, motor impairment, and teratogenesis. In the quest for new antiepileptic drugs, animal venoms offer a valuable source of neuroactive molecules targeting ion channels and neurotransmitter receptors. This study investigates the antiepileptic potential of compounds isolated from the venom of the Parawixia bistriata spider. One compound, designated Parawixin-11, demonstrated significant anticonvulsant effects when injected into the cerebral ventricle in a dose-response manner. It effectively countered seizures induced by bicuculline (ED50 0.16 µg/animal), pentylenetetrazole (ED50 0.08 µg/animal), strychnine (ED50 0.05 µg/animal), pilocarpine (ED50 0.10 µg/animal), and NMDA (ED50 0.008 µg/animal). We also assessed whether intracerebroventricular administration of Parawixin-11 caused motor or cognitive impairments in rats using the open field, rotarod, and Morris water maze tests. No differences in exploration or movement were observed with doses of 0.3, 0.2, or 0.1 µg of Parawixin-11. Although there was an increased latency to find the platform during the acquisition phase of the Morris water maze test, no differences in spatial memory retention were noted. Given Parawixin-11's potency against NMDA-induced seizures, we hypothesize that it may modulate the glutamatergic system, aligning with the mechanisms of several spider-derived polyamines.
Identifiants
pubmed: 39042155
doi: 10.1007/s00210-024-03299-x
pii: 10.1007/s00210-024-03299-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Beleboni RO, Guizzo R, Fontana ACK, Pizzo AB, Carolino RO, Gobbo-Neto L, Lopes NP, Coutinho-Netto J, Santos WF (2006) Neurochemical characterization of a neuroprotective compound from Parawixia bistriata spider venom that inhibits synaptosomal uptake of GABA and glycine. Mol Pharmacol 69:1998–2006. https://doi.org/10.1124/mol.105.017319
doi: 10.1124/mol.105.017319
pubmed: 16551783
Beleboni RO, Mortari MR, Melo-Thomas L, Coimbra NC (2022) Classical and modern biotechnology applied to the treatment of epilepsy and anxiety disorders. Front Pharmacol 12:824986. https://doi.org/10.3389/fphar.2021.824986
Beleboni RO, Pizzo AB, Fontana ACK, Carolino ROG, Coutinho-Netto J, Santos WF (2004) Spider and wasp neurotoxins: pharmacological and biochemical aspects. Eur J Pharmacol 17:1–17. https://doi.org/10.1016/j.ejphar.2004.03.049
Brancati VU, Vraca PV, Minutoli L, Pallio G (2023) Polymorphisms affecting the response to novel antiepileptic drugs. Int J Mol Sci 24(3):2535. https://doi.org/10.3390/ijms24032535
Bubser M, Keseberg U, Notz PK, Schmidt WJ (1992) Differential behavioural and neurochemical effects of competitive and noncompetitive NMDA receptor antagonists in rats. Eur J Pharmacol 229:75–82. https://doi.org/10.1016/0014-2999(92)90288-f
Cairrão MAR, Ribeiro AM, Pizzo AB, Fontana ACK, Beleboni RO, Coutinho-Netto J, Miranda A, Santos WF (2002) Anticonvulsant and GABA uptake inhibition properties of P. bistriata and S. raptoria spider venom fractions. Pharmacol Biol 40:472–477. https://doi.org/10.1076/phbi.40.6.472.8436
doi: 10.1076/phbi.40.6.472.8436
Castellano C, Cestari V, Ciamei A (2001) NMDA receptors and learning and memory processes. Curr Drug Targets 2(3):273–83. https://doi.org/10.2174/1389450013348515
doi: 10.2174/1389450013348515
pubmed: 11554552
Chow CY, Absalom N, Biggs K, King GF, Ma L (2020) Venom-derived modulators of epilepsy-related ion channels. Biochem Pharmacol 181:114043. https://doi.org/10.1016/j.bcp.2020.114043
Danysz W, Essmann U, Bresink I, Wilke R (1994) Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol Biochem Behav 48:111–118. https://doi.org/10.1016/0091-3057(94)90506-1
doi: 10.1016/0091-3057(94)90506-1
pubmed: 8029281
Fachim HA, Cunha AO, Pereira AC, Beleboni RO, Gobbo-Neto L, Lopes NO, Coutinho-Netto J, dos Santos WF (2011) Neurobiological activity of Parawixin 10, a novel anticonvulsant compound isolated from Parawixia bistriata spider venom (Araneidae: Araneae). Epilepsy Behav 22:158–64. https://doi.org/10.1016/j.yebeh.2011.05.008
doi: 10.1016/j.yebeh.2011.05.008
pubmed: 21763206
Fattorusso A, Matricardi S, Mencaroni E, Dell’Isola GB, Di Cara G, Striano P, Verrotti A (2021) The pharmacoresistant epilepsy: an overview on existent and new emerging therapies. Front Neurol 12:674483. https://doi.org/10.3389/fneur.2021.674483
Finney, D J. (1971) Probit analysis, 3rd Edition. Cambridge University Press, London, p 368
Fontana AC, Guizzo R, Beleboni RO, Meirelles e Silva AR, Coimbra NC, Amara SG, Santos WF, Coutinho-Neto J, (2003) Purification of a neuroprotective component of Parawixia bistriata spider venom that enhances glutamate uptake. Br J Pharmacol 139:1297–1309. https://doi.org/10.1038/sj.bjp.0705352
doi: 10.1038/sj.bjp.0705352
pubmed: 12890709
pmcid: 1573954
Fontana AC, Beleboni RO, Wojewodzic MW, dos Santos WF, Coutinho-Netto J, Grutle NJ, Watts SD, Danbolt NC, Amara SG (2007) Enhancing glutamate transport: mechanism of action of parawixin1, a neuroprotective compound from Parawixia bistriata spider venom. Mol Pharmacol 72(5):1228–37. https://doi.org/10.1124/mol.107.037127
doi: 10.1124/mol.107.037127
pubmed: 17646426
Forster YM, Green JL, Khatiwada A, Liberato JL, Narayana Reddy PA, Salvino JM, Bienz S, Bigler L, Dos Santos WF, Karklin Fontana AC (2020) Elucidation of the structure and synthesis of neuroprotective low molecular mass components of the Parawixia bistriata spider venom. ACS Chem Neurosci (11):1573–1596. https://doi.org/10.1021/acschemneuro.0c00007
Gaidin SG, Kosenkov AM (2023) Calcium-permeable AMPA receptors: an underestimated pharmacological target for the therapy of brain pathologies. Neural Regen Res 18(12):2669–70. https://doi.org/10.4103/1673-5374.373714
doi: 10.4103/1673-5374.373714
pubmed: 37449615
pmcid: 10358676
Gazerani P (2024) Can venoms be used in neuroprotection? Chapter 3. In: Natural molecules in neuroprotection and neurotoxicity. Elsevier Inc. https://doi.org/10.1016/B978-0-443-23763-8.00003-8
Gelfuso EA, Cunha AO, Mortari MR, Liberato JL, Paraventi KH, Beleboni RO, Coutinho-Netto J, Lopes NP, dos Santos WF (2007) Neuropharmacological profile of FrPbAII, purified from the venom of the social spider Parawixia bistriata (Araneae, Araneidae), in Wistar rats. Life Sci 80:566–72. https://doi.org/10.1016/j.lfs.2006.10.002
doi: 10.1016/j.lfs.2006.10.002
pubmed: 17083949
Green JL, Dos Santos WF, Fontana ACK (2021) Role of glutamate excitotoxicity and glutamate transporter EAAT2 in epilepsy: opportunities for novel therapeutics development. Biochem Pharmacol 193:114786. https://doi.org/10.1016/j.bcp.2021.114786
Guscott MR, Clarke HF, Murray F, Grimwood S, Bristow LJ, Hutson PH (2003) The effect of (+/-)-CP-101,606, an NMDA receptor NR2B subunit selective antagonist, in the Morris watermaze. Eur J Pharmacol 476:193–9. https://doi.org/10.1016/s0014-2999(03)02182-4
doi: 10.1016/s0014-2999(03)02182-4
pubmed: 12969766
Kaplan YC, Demir O (2021) Use of phenytoin, phenobarbital carbamazepine, levetiracetam lamotrigine and valproate in pregnancy and breastfeeding: risk of major malformations, dose-dependency, monotherapy vs polytherapy, pharmacokinetics and clinical implications. Curr Neuropharmacol 19(11):1805–1824. https://doi.org/10.2174/1570159X19666210211150856
doi: 10.2174/1570159X19666210211150856
pubmed: 33573557
pmcid: 9185784
Kumar P, Sheokand D, Grewal A, Saini V, Kumar A (2023) Clinical side-effects based drug repositioning for anti-epileptic activity. J Biomol Struct Dyn 12:1–12. https://doi.org/10.1080/07391102.2023.2199874
doi: 10.1080/07391102.2023.2199874
Lamberty Y, Klingaard H (2000) Consequences of pentylenotetrazole-induced kindling on spational memory and emotional responding in the rat. Epilepsy Behav 1:256–61. https://doi.org/10.1006/ebeh.2000.0085
doi: 10.1006/ebeh.2000.0085
pubmed: 12609441
Lima LS, Loyola V, Bicca JVM, Faro L, Vale CLC, Lotufo Denucci B, Mortari MR (2022) Innovative treatments for epilepsy: venom peptides, cannabinoids, and neurostimulation. J Neurosci Res 100:1969–1986. https://doi.org/10.1002/jnr.25114
doi: 10.1002/jnr.25114
pubmed: 35934922
Löscher W (1998) New visions in the pharmacology of anticonvulsion. Eur J Pharmacol 342(1):1–13. https://doi.org/10.1016/s0014-2999(97)01514-8
doi: 10.1016/s0014-2999(97)01514-8
pubmed: 9544786
Löscher W, Klein P (2021) The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond. CNS drugs 35(9):935–63. https://doi.org/10.1007/s40263-021-00853-6
doi: 10.1007/s40263-021-00853-6
pubmed: 34145528
pmcid: 8408078
Mellor IR, Usherwood PNR (2004) Targeting ionotropic receptors with polyamine-containing toxins. Toxicon 43:493–508. https://doi.org/10.1016/j.toxicon.2004.02.003
doi: 10.1016/j.toxicon.2004.02.003
pubmed: 15066409
Morris RP, Garrud P, Rawlins JNP, O’Keefe J (1982) Place navigation impaired in rats with hippocampal lesions. Nature 297:681–683. https://doi.org/10.1038/297681a0
doi: 10.1038/297681a0
pubmed: 7088155
Mortari MR, Cunha AOS, Ferreira LB, Santos WF (2007) Neurotoxins from invertebrates as anticonvulsants: from basic research to therapeutic application. Pharmacol Ther 114:171–83. https://doi.org/10.1016/j.pharmthera.2007.01.009
doi: 10.1016/j.pharmthera.2007.01.009
pubmed: 17399793
Mortari MR, Cunha AOS, Dos Anjos LC, Amaral HO, Quintanilha MVT, Gelfuso EA, Homem-de-Mello M, de Almeida H, Rego S, Maigret B, Lopes NP, Dos Santos WF (2023) A new class of peptides from wasp venom: a pathway to antiepileptic/neuroprotective drugs. Brain Commun 5(1):fcad016. https://doi.org/10.1093/braincomms/fcad016
Paxinos G, Watson C (1997) The rat brain in stereotaxic coordinates. (Third Edition). 286 p. Academic Press, Inc. Sidney. International Standard Book Number: 0-12-547623-X
Perucca E (2019) Antiepileptic drugs: evolution of our knowledge and changes in drug trials. Epileptic Disord 21(4):319–329. https://doi.org/10.1684/epd.2019.1083
doi: 10.1684/epd.2019.1083
pubmed: 31403463
Pinel JP, Rovner LI (1978) Experimental epileptogenesis; kindling-induced epilepsy in rats. Exp Neurol 58:190–202. https://doi.org/10.1016/0014-4886(78)90133-4
doi: 10.1016/0014-4886(78)90133-4
pubmed: 618743
Racine RJ (1972) Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalogr Clin Neurophysiol 32(3):281–94. https://doi.org/10.1016/0013-4694(72)90177-0
doi: 10.1016/0013-4694(72)90177-0
pubmed: 4110397
Speller J, Westby GWM (1996) Bicuculline-induced circling from the rat superior colliculus is blocked by GABA microinjection into deep cerebellar nuclei. Exp Brain Res 110:425–434. https://doi.org/10.1007/BF00229142
doi: 10.1007/BF00229142
pubmed: 8871101
Thijs RD, Surges R, O’Brien TJ, Sander JW (2019) Epilepsy in adults. Lancet 393(10172):689–701. https://doi.org/10.1016/S0140-6736(18)32596-0
doi: 10.1016/S0140-6736(18)32596-0
pubmed: 30686584
Usherwood PNR, Blagbrough IS (1994) Spider toxins affecting glutamate receptors: Polyamines in therapeutic neurochemistry. Pharmacol Teratol 52:245–268. https://doi.org/10.1016/0163-7258(91)90012-b
doi: 10.1016/0163-7258(91)90012-b
Vassilevski AA, Kozlov SA, Grishin EV (2009) Molecular diversity of spider venom. Biochemistry 74:1505–1534. https://doi.org/10.1134/s0006297909130069
doi: 10.1134/s0006297909130069
pubmed: 20210706
Wahab A (2010) Difficulties in treatment and management of epilepsy and challenges in new drug development. Pharmaceuticals 3:2090–2110. https://doi.org/10.3390/ph3072090
doi: 10.3390/ph3072090
pubmed: 27713344
pmcid: 4036655